Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

25770.2 PFLS-LS

Projekttitel

Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Deutsch)	Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by Notch pathway activation to be selected for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Kurzbeschreibung (Englisch)
Abstract (Deutsch)	Development of a proprietary biomarker based companion diagnostic for identification and selection of cancer patients with disease driven by NOTCH pathway activation, for treatment with Cellestia`s first-in-class pan NOTCH inhibitor and clinical development candidate drug CB-103.
Abstract (Englisch)